{"id":186424,"date":"2022-05-26T00:00:00","date_gmt":"2022-05-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/47037337-medtech-interventional-cardiology-devices-market\/"},"modified":"2026-03-31T10:14:06","modified_gmt":"2026-03-31T10:14:06","slug":"47037337-medtech-interventional-cardiology-devices-market-insights-canada","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47037337-medtech-interventional-cardiology-devices-market-insights-canada\/","title":{"rendered":"Interventional Cardiology Devices &#8211; Market Insights &#8211; Canada"},"content":{"rendered":"<p>Despite the negative impact of the <abbr title=\"Coronavirus Disease 2019\">COVID-19<\/abbr> pandemic in the short term, the Canadian <abbr title=\"Interventional Cardiology\">IC<\/abbr> device market will <span>grow minimally<\/span> through 2031, driven by an aging population, expanding <abbr title=\"Coronary Artery Disease\">CAD<\/abbr> patient pool, an increasing prevalence of complex lesions, and the emergence of specialized premium-priced technologies to diagnose and treat these complex <abbr title=\"Coronary Artery Disease\">CAD<\/abbr>s\u2014such as next-generation <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr>, <abbr title=\"Bioresorbable Scaffold(s)\">BRS<\/abbr>, and intravascular imaging catheters and pressure guidewires\u2014supporting revenues. These areas of growth will offset <abbr title=\"Average Selling Price\">ASP<\/abbr> <span>declines <\/span>due to intense price competition across all market segments.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for <abbr title=\"Interventional Cardiology\">IC<\/abbr> devices in Canada, with market projections across a 12-year period.<\/p>\n<p class=\"question-statement\"><b>A number of flagship devices were launched in recent years in the highly competitive <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr> market.<\/b><\/p>\n<p>How have market dynamics changed between the three major competitors recently?<\/p>\n<p>What competitive strategies are the major competitors implementing to gain share in this market?<\/p>\n<p>What is the developmental pipeline for the next generation of <abbr title=\"Bioresorbable Scaffold(s)\">BRS<\/abbr>?<\/p>\n<p class=\"question-statement\"><strong>The continued launch of newer <abbr title=\"Bioresorbable Scaffold(s)\">BRS<\/abbr> and <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s will drive a shift in device preference in procedures that have traditionally been performed with <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr> or <abbr title=\"Bare-Metal Stent(s)\">BMS<\/abbr>, respectively.<\/strong><\/p>\n<p>How are current recommendations for use dictating adoption of <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr>, <abbr title=\"Bare-Metal Stent(s)\">BMS<\/abbr>, and <abbr title=\"Bioresorbable Vascular Scaffold(s)\">BRS<\/abbr> for <abbr title=\"Coronary Artery Disease\">CAD<\/abbr> patients?<\/p>\n<p>What is the evolving role of <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s in <abbr title=\"Percutaneous Coronary Intervention\">PCI<\/abbr>s in the current clinical landscape?<\/p>\n<p><b>Emerging technologies designed to diagnose and treat complex <abbr title=\"Percutaneous Coronary Intervention\">PCI<\/abbr>s are expected to receive approval in Canada in the near future.<\/b><\/p>\n<p>How will the adoption of alternative coronary physiology modalities such as resting indices, angiography-based <abbr title=\"Fractional Flow Reserve\">FFR<\/abbr>, and noninvasive <abbr title=\"Fractional Flow Reserve\">FFR<\/abbr><sub><abbr title=\"Computed Tomography\">CT<\/abbr><\/sub> alter patient and procedure compositions in cardiac catheterization labs?<\/p>\n<p>What is the status and expected impact of emerging balloon-based technologies such as <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s and coronary lithotripsy?<\/p>\n<p><b>The Canada <abbr title=\"Interventional Cardiology\">IC<\/abbr> device market has been impacted by the <abbr title=\"Coronavirus Disease 2019\">COVID-19<\/abbr> pandemic in the short term.<\/b><\/p>\n<p>What factors have contributed to market declines?<\/p>\n<p>To what degree has the pandemic affected different procedures and devices?<\/p>\n<p>How soon will procedure volumes, sales, and revenues recover?<\/p>\n","protected":false},"template":"","class_list":["post-186424","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-therapy-area-interventional-cardiology-devices","medtech-geography-canada","medtech-date-967"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186424\/revisions"}],"predecessor-version":[{"id":282151,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/186424\/revisions\/282151"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=186424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}